Sanofi will cut 229 positions in Massachusetts, the company notified state officials in a filing that identifies the affected staff as employees of Blueprint Medicines. The Cambridge-based biotech was acquired by Sanofi in July 2025 in a transaction valued at $9.1 billion, and the recent submission to authorities outlines the scope of planned reductions.
The document lodged with the state’s Executive Office of Labor and Workforce Development sets the window for job eliminations between Oct. 9, 2026 and late June 2027. The filing serves as the formal notification of workforce change to the state agency; a link to that office is provided here: Executive Office of Labor and Workforce Development. Sanofi is counted among the larger pharmaceutical employers operating in the state, and the filing specifies the number and timing of the cuts without detailing individual roles.
The notice highlights adjustments at a unit that was integrated into Sanofi following the takeover of Blueprint Medicines. Companies in the sector commonly file such notices when reorganizations or consolidations of operations are planned; the record lodged with state officials provides the principal public details — headcount and schedule — that regulators and local stakeholders will use to track the transition. The affected workforce is part of Cambridge’s wider biotech and pharmaceutical ecosystem, which has seen significant deal activity in recent years.
State and local workforce offices typically monitor filings of this type to coordinate services and resources for departing employees. The filing from Sanofi sets the official timeline; further operational particulars and any company statements beyond the notice have not been included in the public filing. Observers and affected workers will look to subsequent updates from the company and the state agency for information about next steps and available support.
